ABCL Q4 2022 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M-84.5% YoY

Gross Profit

$20M92.8% margin

Operating Income

-$38M-175.3% margin

Net Income

-$30M-138.7% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-78.7%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$19M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$308M

Stockholders' Equity

$1.2B

Cash & Equivalents

$387M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$139M	-84.5%
Gross Profit	$20M	$117M	-83.0%
Operating Income	-$38M	$82M	-146.3%
Net Income	-$30M	$60M	-149.9%

Revenue Segments

Research Fees

$11M53%

Royalty

$9M44%

Milestone Payments

$500,0002%

License

$165,0001%